Transport Pharma Targets Cold Sores With Drug-Device Combination Product
This article was originally published in The Gray Sheet
Executive Summary
A combination product that delivers drugs through the skin via low-voltage electric current could represent an affordable approach to treating cold sores, according to Transport Pharmaceuticals
You may also be interested in...
J&J Ionsys fentanyl pump for post-surgical pain to launch in 2007
Johnson & Johnson subsidiary Alza will launch in 2007 its Ionsys needle-free, patient-activated iontophoresis transdermal fentanyl drug delivery system for post-operative pain, the firm says. FDA approved the system May 22 for short-term management of post-operative pain in adults requiring opioid analgesia during hospitalization. Ionsys' E-Trans delivery technology uses low-intensity electrical current to move a 40 mcg dose of fentanyl from a reservoir into the skin over a 10-minute period. Alza also markets the controlled-release fentanyl patch Duragesic. The road to approval for Ionsys has been relatively long. A September 2003 NDA filing was deemed "approvable" in July 2004. The company resubmitted the application in November 2005...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.